All In Biotech

Drug Trial Radar · NCT02105467

Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.

Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 421 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

421

Actual

Start

Jun 5, 2014

Primary completion

Feb 26, 2015

Study completion Sep 6, 2015

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection. Participants were randomly assigned (3:1 ratio) to immediate treatment or deferred treatment (placebo control). The primary efficacy hypothesis was that the proportion of participants receiving combination therapy in the Immediate Treatment Arm who achieve sustained viral response at 12 weeks after the end of study treatment (SVR12) is superior to 73%.

Conditions

  • Chronic Hepatitis C Virus

Interventions

  • Grazoprevir 100mg / Elbasvir 50 mg FDCDrug

  • Placebo to Grazoprevir / Elbasvir 50 mg FDCDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)Time frame: Week 24 (12 weeks after the end of treatment)
  2. Percentage of Participants Experiencing at Least One Adverse EventTime frame: Up to Week 14 (14 days after the Blinded Treatment was completed)
  3. Percentage of Participants Discontinued From Study Treatment Because of an Adverse EventTime frame: Up to Week 12 (end of Blinded Treatment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.